ストックスクリーナーアプリを入手
16.97
4.11%
0.67
アフターアワーズ：
17.00
0.03
+0.18%
Nurix Therapeutics Inc (NRIX) 最新ニュース
Nurix Therapeutics shares edge higher despite Q1 earnings miss - MSN
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Does Nurix Therapeutics (NRIX) have the potential to rally 85.84% as Wall Street analysts expect? - MSN
Q2 EPS Estimate for Nurix Therapeutics Lifted by Analyst - MarketBeat
NRIX: Lead BTK degrader enters phase III for CLL, with strong efficacy and robust financial runway - TradingView — Track All Markets
NRIX: Lead BTK degrader enters phase III in CLL, with strong efficacy and broad pipeline momentum - TradingView — Track All Markets
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Weakness - Sahm
(NRIX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Did Sanofi Revenue Expiry and Rising R&D Spend Just Recast Nurix Therapeutics' (NRIX) Investment Narrative? - Yahoo Finance
Does Wall Street Predict an 85.84% Surge for Nurix Therapeutics (NRIX)? - Bitget
Nurix Therapeutics, Inc. (NRIX) reports Q1 loss, lags revenue estimates - MSN
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect? - Yahoo Finance
Growth Report: Can Nurix Therapeutics Inc sustain its profitabilityWeekly Trade Recap & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
HC Wainwright Reaffirms Buy Rating on NRIX with $32 Target | NRI - GuruFocus
Nurix Therapeutics' (NRIX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
How Weaker Q1 Results And Advancing Bexobrutideg Trials At Nurix Therapeutics (NRIX) Have Changed Its Investment Story - Sahm
RBC Capital Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Truist Financial Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics Inc reports results for the quarter ended February 28Earnings Summary - TradingView — Track All Markets
Portfolio Recap: Is Nurix Therapeutics Inc undervalued by DCF analysis2026 Year in Review & Safe Capital Growth Plans - baoquankhu1.vn
NRIX: Wells Fargo Adjusts Price Target while Maintaining Overwei - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Price Target Cut to $28.00 by Analysts at Wells Fargo & Company - MarketBeat
Wells Fargo cuts Nurix stock price target on CLL trial timing - Investing.com
Nurix Therapeutics (NRIX) Heavy Q1 Net Loss Reinforces Bearish Narrative On Profitability - Sahm
Inside Nurix Therapeutics Inc (NRIX): A Comprehensive SWOT Break - GuruFocus
Inside Nurix Therapeutics Inc (NRIX): A Comprehensive SWOT Breakdown - GuruFocus
Nurix Therapeutics (NRIX) Stock Declines Amid Expanding Losses and R&D Investment - mexc.co
NRIX: Needham Reiterates Buy Rating with Target Price of $26.00 - GuruFocus
Nurix Therapeutics (NRIX) Stock: Slides as Losses Widen Despite Pipeline Progress - CoinCentral
Needham & Company LLC Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Nurix Advances NX-5948 Into Phase 3 Head-to-Head Battle in CLL/SLL - TipRanks
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Bitget
Nurix Therapeutics, Inc. (NRIX) Posts Q1 2026 Results - AlphaStreet
Nurix Therapeutics stocks rise 3% despite Q1 miss - Investing.com
Nurix Therapeutics stocks rise 3% despite Q1 miss By Investing.com - Investing.com South Africa
Nurix Therapeutics, Inc. Q1 2026 Financial Results: Continued R&D Investment, Collaboration Revenue, and Key Risk Factors Highlighted in 10-Q Filing - Minichart
Nurix Therapeutics (NRIX) Q1 FY2026 Earnings: EPS -$0.79 (Miss v - GuruFocus
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2026 - marketscreener.com
Nurix Therapeutics Reports Q1 2026 Financial Results and Corporate Update - Minichart
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
NRIX Reports Lower Q1 Revenue; Focuses on Key Medical Developmen - GuruFocus
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Nurix Therapeutics Fiscal Q1 Loss Widens, Revenue Falls - marketscreener.com
[10-Q] Nurix Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Earnings Flash (NRIX) Nurix Therapeutics Posts Fiscal Q1 Loss $0.79 a Share, vs. FactSet Est of $0.76 Loss - marketscreener.com
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q1 Revenue $6.3M, vs. FactSet Est of $14.3M - marketscreener.com
Nurix Therapeutics 3Q 2026: Revenue $6.25M, EPS $(0.79) — 10-Q Summary - TradingView — Track All Markets
Nurix Therapeutics Q1 loss widens on higher costs - TradingView
NRIX: Q1 2026 saw pipeline progress, higher R&D costs, and a strong cash position amid lower revenue - TradingView — Track All Markets
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):